Evidence map›Paper›PMID 41068524›Full record

ReviewStem cell reviews and reports2026

A New Vision for Ocular Disease: Stem Cell Strategies in Regenerative Ophthalmology.

Sadhnakumari Chourasiya, Pratixa Patel, G Santhana Kumar, Arun Soni

Abstract readReview
PubMed Publisher
In one paragraph

Review in Stem cell reviews and reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Sadhnakumari ChourasiyaDepartment of Pharmacology, ROFEL, Shri G.M. Bilakhia College of Pharmacy, Rajju Shroff Rofel University, Vapi, Gujarat, 396191, India. sadhnajayambevapi@gmail.com.
Pratixa PatelDepartment of Pharmacology, ROFEL, Shri G.M. Bilakhia College of Pharmacy, Rajju Shroff Rofel University, Vapi, Gujarat, 396191, India.
G Santhana KumarDepartment of Pharmaceutical Sciences, Faculty of Health Sciences, Marwadi University, Rajkot, Gujarat, 360003, India.
Arun SoniDepartment of Pharmacology, Ramanbhai Patel College of Pharmacy, CHARUSAT, Changa, Gujarat, 388421, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Degenerative ocular diseases such as age-related macular degeneration (AMD), glaucoma, cataracts, retinitis pigmentosa (RP), dry eye disease (DED), and limbal stem cell deficiency (LSCD) are major contributors to global visual impairment and blindness. These conditions not only affect vision but also significantly reduce patients’ quality of life. Conventional therapies largely aim to manage symptoms or slow disease progression, with limited ability to regenerate or restore damaged ocular tissues. In contrast, stem cell-based therapies have emerged as a promising strategy, offering the potential to repair, replace, or regenerate dysfunctional cells within the eye. Stem cells exhibit remarkable regenerative, anti-inflammatory, and neuroprotective properties, mediated both by direct differentiation and through paracrine mechanisms such as the secretion of growth factors and exosomes. A wide range of stem cell types—mesenchymal stem cells (MSCs), retinal progenitor cells (RPCs), induced pluripotent stem cells (iPSCs), and embryonic stem cells (ESCs)—are currently under investigation for the treatment of diverse ophthalmic conditions. These therapies target various ocular structures, from the cornea to the retina, aiming to restore tissue integrity and function. This review highlights the current progress, mechanisms, and therapeutic potential of stem cell applications in ocular regeneration, and underscores their growing relevance as a regenerative solution for previously untreatable or refractory eye diseases and the clinical trials that are currently ongoing.

Indexed as

Eye DiseasesRegenerative MedicineStem CellsStem Cell TransplantationAnimalsHumansInduced Pluripotent Stem CellsLimbal Stem Cell DeficiencyClinical trialsOphthalmic diseasesRegenerative medicineRetinal degenerationStem cells

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.